<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This study evaluated the effects of <z:chebi fb="0" ids="5959">irbesartan</z:chebi> and <z:chebi fb="2" ids="8499">propranolol</z:chebi> on thyroid hormone (TH)-induced cardiac functional and structural remodeling </plain></SENT>
<SENT sid="1" pm="."><plain>A rat model of <z:e sem="disease" ids="C0040156" disease_type="Disease or Syndrome" abbrv="">thyrotoxicosis</z:e> was established by daily intraperitoneal injections of <z:chebi fb="0" ids="18332">L-thyroxine</z:chebi> (T&lt;inf&gt;4&lt;/inf&gt;, 100 µg/kg) for 4 weeks </plain></SENT>
<SENT sid="2" pm="."><plain>Forty Sprague-Dawley rats were randomly divided into four groups (n = 10 each): control group, T&lt;inf&gt;4&lt;/inf&gt; group (T&lt;inf&gt;4&lt;/inf&gt; alone), T&lt;inf&gt;4&lt;/inf&gt; plus <z:chebi fb="0" ids="5959">irbesartan</z:chebi> group (T&lt;inf&gt;4&lt;/inf&gt;-Irb, 30 mg/kg), and T&lt;inf&gt;4&lt;/inf&gt; plus <z:chebi fb="2" ids="8499">propranolol</z:chebi> group (T&lt;inf&gt;4&lt;/inf&gt;-Pro, 0.5mg/mL of drinking water) </plain></SENT>
<SENT sid="3" pm="."><plain>Cardiac chamber size and functional parameters were measured by echocardiography and cardiomyocyte diameter </plain></SENT>
<SENT sid="4" pm="."><plain>Heart rate (HR) and <z:mp ids='MP_0003141'>cardiac fibrosis</z:mp> were determined </plain></SENT>
<SENT sid="5" pm="."><plain>T&lt;inf&gt;4&lt;/inf&gt; alone showed significantly increased HR and cardiomyocyte width (25.0 ± 1.77 vs. 18.8 ± 0.84 µm, P &lt; 0.001) with <z:mp ids='MP_0003045'>fibrosis</z:mp>, reduced left ventricle (LV) longitudinal strain (S&lt;inf&gt;long&lt;/inf&gt;; -16.0 ± 6.27 vs. -22.7 ± 5.19 %, P &lt; 0.001) compared with control </plain></SENT>
<SENT sid="6" pm="."><plain>When compared with T&lt;inf&gt;4&lt;/inf&gt; alone, T&lt;inf&gt;4&lt;/inf&gt;-Irb showed significantly improved LV S&lt;inf&gt;long&lt;/inf&gt; (-21.4 ± 1.84 vs. -16.0 ± 6.27 %, P =0.017) and reduced cardiomyocyte width (21.0 ± 1.0 vs. 25.0 ± 1.77 µm, P =0.002) with comparable HR (458.4 ± 24.3 vs. 486.6 ± 30.1 bpm, P = 0.086) </plain></SENT>
<SENT sid="7" pm="."><plain>However, T&lt;inf&gt;4&lt;/inf&gt;-Pro showed significantly reduced HR with improved LV S&lt;inf&gt;long&lt;/inf&gt; without alteration of cardiomyocyte width and <z:mp ids='MP_0003045'>fibrosis</z:mp> compared with T&lt;inf&gt;4&lt;/inf&gt; alone </plain></SENT>
<SENT sid="8" pm="."><plain>In conclusion, renin-angiotensin system (<z:mp ids='MP_0011356'>RAS</z:mp>) blocking by <z:chebi fb="0" ids="5959">irbesartan</z:chebi> could significantly attenuate TH-induced cardiac structural and functional remodeling </plain></SENT>
<SENT sid="9" pm="."><plain>However, HR reduction by <z:chebi fb="2" ids="8499">propranolol</z:chebi> could not alternate structural remodeling, which may implicate the <z:mp ids='MP_0011356'>RAS</z:mp> as having an important role in thyrotoxic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> beyond <z:hpo ids='HP_0001649'>tachycardia</z:hpo> </plain></SENT>
</text></document>